The Technical Analyst
Arch Therapeutics, Inc. [ARTH]
Exchange: PNK Industry: Biotechnology
Arch Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.42% $0.925
America/New_York / 3 mai 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.39 mill |
| EPS: | -1.400 |
| P/E: | -0.660 |
| Earnings Date: | May 20, 2024 |
| SharesOutstanding: | 4.74 mill |
| Avg Daily Volume: | 0.0033 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.660 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.660 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.669 - 1.181 ( +/- 27.68%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-31 | Abrams Michael S | Buy | 20 584 | Warrants (right to buy) |
| 2023-08-31 | Abrams Michael S | Buy | 10 292 | Common Stock |
| 2023-08-31 | Norchi Terrence W | Buy | 13 724 | Warrants (right to buy) |
| 2023-08-31 | Norchi Terrence W | Buy | 6 862 | Common Stock |
| 2023-08-31 | Hicks Laurence | Buy | 20 584 | Warrants (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 89 transactions |
| Buy: 27 633 666 | Sell: 2 335 000 |
Forecast:
16:00 - $0.925
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.925
Forecast 2: 16:00 - $0.925
Forecast 3: 16:00 - $0.925
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.925 (-8.42% ) |
| Volume | 0.0104 mill |
| Avg. Vol. | 0.0033 mill |
| % of Avg. Vol | 309.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARTH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Latest Press Releases
2023-11-09 06:50:00 - Press Release
Arch Therapeutics Provides Year End Operational Update
Fiscal year-end ac5 advanced wound system update includes q4 record monthly order volumes, favorable reimbursement decisions and increases in paid claims.
2023-11-02 06:50:00 - Press Release
Arch Therapeutics To Present Ac5® Advanced Wound System At The 2023 Symposium On Advanced Wound Care Fall Meeting (sawc Fall)
Framingham, mass., nov. 02, 2023 (globe newswire) -- arch therapeutics, inc. (otcqb: arth) (“arch” or the “company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the company's first commercial product, ac5 ® advanced wound system (“ac5”), will be featured at the 2023 symposium on advanced wound care fall meeting (“sawc fall”), which takes place at caesars palace, las vegas, from november 2-5, 2023.
2023-09-13 06:45:00 - Press Release
Arch Therapeutics Provides Ac5® Commercialization Update
Orders and paid claims increasing since rollout of reimbursement code orders and paid claims increasing since rollout of reimbursement code
2023-09-07 19:14:00 - Press Release
Arch Therapeutics Completes Financing As Bridge To Uplisting
Common stock listing on national exchange is next planned significant milestone common stock listing on national exchange is next planned significant milestone
2023-04-25 06:50:00 - Press Release
Arch Therapeutics To Present Ac5® Advanced Wound System At 2023 Symposium On Advanced Wound Care (“sawc”)
Sawc spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated ac5 hcpcs reimbursement code sawc spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated ac5 hcpcs reimbursement code
Latest News
2023-12-27 11:17:51 - Zacks Investment Research
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
Here is how Arch Therapeutics, Inc. (ARTH) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
2023-12-11 11:18:26 - Zacks Investment Research
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
Here is how Arch Therapeutics, Inc. (ARTH) and Haemonetics (HAE) have performed compared to their sector so far this year.
2023-11-23 11:17:19 - Zacks Investment Research
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
2023-11-02 06:50:00 - GlobeNewsWire
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company's first commercial product, AC5 ® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanced Wound Care Fall Meeting (“SAWC Fall”), which takes place at Caesars Palace, Las Vegas, from November 2-5, 2023.
2023-04-25 06:50:00 - GlobeNewsWire
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement code SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement code
2022-09-20 06:50:00 - GlobeNewsWire
Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic Products in Wound Healing Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic Products in Wound Healing
2021-10-25 07:50:00 - GlobeNewsWire
Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall
AC5® Advanced Wound System Selected for Innovation Spotlight AC5® Advanced Wound System Selected for Innovation Spotlight
2021-10-18 07:50:00 - GlobeNewsWire
Arch Therapeutics Launches Experts in Wound Care Program
Key Opinion Leaders Share Insights on Advancing Wound Care Key Opinion Leaders Share Insights on Advancing Wound Care
2021-10-13 16:30:00 - GlobeNewsWire
Arch Therapeutics Provides Corporate Update
2021-10-06 07:50:00 - GlobeNewsWire
Arch Therapeutics to Present at the LD Micro Main Event
